Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progressive Multifocal Leukoencephalopathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Progressive Multifocal Leukoencephalopathy. Displaying page 1 of 1.
    EudraCT Number: 2008-001314-24 Sponsor Protocol Number: 111JC101 Start Date*: 2009-01-02
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)
    Medical condition: Progressive Multifocal Leukoencephalopathy (PML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036807 Progressive multifocal leukoencephalopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000725-41 Sponsor Protocol Number: CLI-107-15 Start Date*: 2013-01-22
    Sponsor Name:Cytheris S.A.
    Full Title: A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy.
    Medical condition: HIV-infected patients with Progressive Multifocal Leukoencephalopathy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10036807 Progressive multifocal leukoencephalopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002566-13 Sponsor Protocol Number: NEXT-MS Start Date*: 2019-12-19
    Sponsor Name:Amsterdam University Medical Center
    Full Title: Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10070425 Multiple sclerosis exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020369-26 Sponsor Protocol Number: 101JC404 Start Date*: 2010-11-29
    Sponsor Name:Biogen Idec
    Full Title: High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab
    Medical condition: Immune Reconstitution Inflammatory Syndrome
    Disease: Version SOC Term Classification Code Term Level
    12.1 10054014 Immune reconstitution syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004435-72 Sponsor Protocol Number: GA28951 Start Date*: 2014-10-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II/III STUDIES
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Prematurely Ended) DE (Ongoing) CZ (Prematurely Ended) DK (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) AT (Completed) PT (Prematurely Ended) EE (Prematurely Ended) NL (Prematurely Ended) NO (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) BE (Prematurely Ended) HR (Completed) IT (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) BG (Completed) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003855-76 Sponsor Protocol Number: GA29145 Start Date*: 2015-08-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144
    Medical condition: Crohn`s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) EE (Ongoing) LT (Prematurely Ended) LV (Prematurely Ended) HU (Ongoing) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) SK (Prematurely Ended) CZ (Prematurely Ended) BE (Prematurely Ended) AT (Completed) FR (Ongoing) HR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003409-36 Sponsor Protocol Number: GA27927 Start Date*: 2011-11-14
    Sponsor Name:Genentech, Inc.
    Full Title: A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of rhuMAb Beta7 in Patients with Moderate to Severe Ulcerative Colitis
    Medical condition: Ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2023-000018-16 Sponsor Protocol Number: OZA22/IM047-048 Start Date*: 2023-04-19
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study
    Medical condition: Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002765-34 Sponsor Protocol Number: MabionCD20-003RA Start Date*: 2021-10-21
    Sponsor Name:Mabion S.A.
    Full Title: A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Similarity Between MabionCD20 (manufactured in commercial scale), EU-approved MabThera® and US-licen...
    Medical condition: Moderate-to-severe rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003649-10 Sponsor Protocol Number: CA40192 Start Date*: 2018-03-13
    Sponsor Name:Roche Farma S.A. (Soc unipersonal) que realiza el ensayo en España y que actúa como represntante de FHoffmann-La Roche
    Full Title: A PHASE I, OPEN–LABEL, RANDOMIZED, PHARMACOKINETIC, PHARMACODYNAMIC, AND SAFETY STUDY OF ETROLIZUMAB FOLLOWED BY OPEN–LABEL EXTENSION AND SAFETY MONITORING IN PEDIATRIC PATIENTS FROM 4 YEARS TO LES...
    Medical condition: Moderate to severe ulcerative colitis (UC); moderate to severe Crohn’s disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) GB (GB - no longer in EU/EEA) PL (Ongoing) DE (Completed) BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000441-38 Sponsor Protocol Number: CPCRA 065 Start Date*: 2005-04-26
    Sponsor Name:National Institute of Allergy and Infectious Diseases, National Institutes of Health
    Full Title: Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)
    Medical condition: HIV infection
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Prematurely Ended) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004061-41 Sponsor Protocol Number: 101-MS-321 Start Date*: 2006-06-01
    Sponsor Name:BIOGEN IDEC LTD
    Full Title: An Open-label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801 o...
    Medical condition: Multiple sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Prematurely Ended) FI (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) SE (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000630-34 Sponsor Protocol Number: MLN0002-3029 Start Date*: 2022-12-09
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Intravenous in Pediatric Patients With Ulcerative Colitis or Crohn’s Disease
    Medical condition: Active Ulcerative Colitis (UC) or Crohn's disease (CD)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Ongoing) PL (Ongoing) CZ (Ongoing) ES (Prematurely Ended) SK (Prematurely Ended) GR (Ongoing) BE (Ongoing) LT (Completed) HR (Ongoing) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2013-003884-71 Sponsor Protocol Number: LPS13649 Start Date*: 2015-02-05
    Sponsor Name:Genzyme Corporation
    Full Title: A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409)
    Medical condition: Relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed) DK (Completed) HR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA